Canada markets open in 47 minutes

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2566-0.0035 (-1.35%)
At close: 04:00PM EST
0.2568 +0.00 (+0.08%)
Pre-Market: 08:38AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.2601
Open0.2580
Bid0.0000 x 800
Ask0.2701 x 1000
Day's Range0.2510 - 0.2692
52 Week Range0.2500 - 3.7900
Volume2,440,272
Avg. Volume3,061,739
Market Cap37.622M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-0.5670
Earnings DateMar. 22, 2022 - Mar. 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • GlobeNewswire

    Abeona Therapeutics Issues Letter to Shareholders

    NEW YORK and CLEVELAND, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders. Dear fellow shareholders, We have never been closer to fulfilling our mission of providing novel gene and cell therapies to patients who currently have no approved treatment options as we continue to advance the EB-101 and ABO-102 pivotal studies toward completion to support two U.S. Biologics Lic

  • GlobeNewswire

    Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants

    NEW YORK and CLEVELAND, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its underwritten public offering of 44,700,000 shares of its common stock and warrants to purchase 44,700,000 shares of its common stock at a combined offering price to the public of $0.39 per one share of common stock and one warrant to purchase one share of common stock. The warrants have an exercise price of $0.39

  • GlobeNewswire

    Abeona Therapeutics Announces Public Offering of Common Stock and Warrants

    NEW YORK and CLEVELAND, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the securities in the offering are to be sold by Abeona. The offering is subject to market conditions, and there can be no assurance as to